Thursday 7 May, 2026
Objectives Radiation therapy (RT) is a standard treatment for thoracic cancers such as lung cancer and lymphoma. However, exposure of…
Read morePoster: Drug/Disease Modelling - Oncology
Development of a mathematical model for the quantitative comparison of RC106 and TMZ efficacy in U87 spheroids
Thursday 7 May, 2026
Introduction: Glioblastoma (GBM) is an aggressive brain tumor with no effective cure. Temozolomide (TMZ) remains the standard chemotherapeutic agent; however,…
Read moreAPPLICATION OF DEEPNLME FRAMEWORK TO CHARACTERIZE DISTINCT PLATELET DYNAMICS IN PATIENTS TREATED WITH MILADEMETAN
Thursday 7 May, 2026
Objectives: Thrombocytopenia is one of the most common adverse events in oncology drug development, which is often a dose-limiting factor…
Read moreA semi-mechanistic model describing tumor response to oncolytic virus and anti-PD-1 therapy in preclinical studies
Thursday 7 May, 2026
Introduction. Oncolytic viruses (OVs) are a promising therapeutic strategy in oncology due to their dual mechanism of action: direct oncolytic…
Read moreAn Integrated Population Pharmacokinetic Analysis of Peg-Asparaginase Across Multiple Nordic Acute Lymphoblastic Leukemia Treatment Protocols: Characterizing Time-Dependent Clearance Dynamics and Patient Factors Driving Variability
Thursday 7 May, 2026
Introduction: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with an estimated 103,727 new cases reported globally in…
Read moreUSE OF VIRTUAL TWINS TO ESTABLISH A PREDICTIVE MODEL BETWEEN SIMULATED IL-6 CONCENTRATIONS AND CRS RISK DURING ODRONEXTAMAB STEP-UP DOSING IN B-CELL LYMPHOMA PATIENTS
Thursday 7 May, 2026
Introduction: Excessive cytokine release following administration of T-cell engagers can trigger life-threatening cytokine-release syndrome (CRS) adverse events. Severe CRS symptoms…
Read moreMechanistic modeling of the natural history of cancer progression and metastatic dissemination in stage I non-small cell lung cancer patients after curative surgery
Thursday 7 May, 2026
Objectives Surgical resection is the standard of care for patients with early-stage non-small lung cancer (NSCLC)1. However, 5 to 10%…
Read morePK/PD modelling and simulations of cambritaxestat-mediated inhibition of autotaxin-lysophosphatidic acid pathway in metastatic pancreatic cancer patients to inform Phase II dose selection
Thursday 7 May, 2026
Background: Autotaxin (ATX) is an enzyme involved in the synthesis of lysophosphatidic acid (LPA), which regulates cell proliferation, migration and…
Read moreAPPLICATION OF IO SIMULATOR IN IMMUNO-ONCOLOGY COMBINATION THERAPY: A SMALL CELL LUNG CANCER CASE STUDY
Thursday 7 May, 2026
Introduction: Over last decade the Quantitative systems pharmacology (QSP) has matured to an approach recognized by regulatory agencies, which is…
Read morePOPULATION PHARMACOKINETICS OF MYCOPHENOLIC ACID IN PATIENTS WITH HIGH-GRADE LOCALLY ADVANCED OR METASTATIC OSTEOSARCOMA
Thursday 7 May, 2026
Objective: Osteosarcoma is the most common primary bone malignancy in children and adolescents, and outcomes remain poor for patients with…
Read more